What is the current stock price of Metagenomi, Inc. Common Stock (MGX)?

As of the latest market data, Metagenomi, Inc. Common Stock (MGX) is trading at $1.38. The stock has seen a loss of -0.72% today.

Does Metagenomi, Inc. Common Stock (MGX) pay a dividend?

Based on current data, Metagenomi, Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of Metagenomi, Inc. Common Stock?

The current market capitalization of Metagenomi, Inc. Common Stock (MGX) is approximately unavailable.

MGX

Metagenomi, Inc. Common Stock·Healthcare

1.38

0.719%(−0.01)

Market Closed

1.42

2.899%(+0.04)

After Hours

Last Updated: — ET

52W L: $1.2552W H: $3.95

MGX NEWS

defenseworld.net

Mar 25

Metagenomi (MGX) to Release Earnings on Wednesday

Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page

defenseworld.net

Mar 23

Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus Target Price from Analysts

Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating

zacks.com

Mar 5

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Metagenomi Therapeutics (MGX) came out with a quarterly loss of $0.6 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.63 per share a year ago.

globenewswire.com

Mar 5

Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company's strategic evolution $160.8 million in cash, cash equivalents and available-for-sale marketable securities as of December 31, 2025 with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported financial results for the full year ended December 31, 2025, and provided business updates.

seekingalpha.com

Mar 4

Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

globenewswire.com

Feb 23

Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference

EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.

Company Profile

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Sector

Healthcare

Industry

Biotechnology

Employees

202

IPO Date

2006-04-06

Beta

0.57

Websitewww.metagenomi.co↗